GLP-1 Agonists
The incretin-based drug class used for appetite control, blood-sugar regulation and fat loss. This hub covers the three compounds most often researched — tirzepatide, semaglutide and retatrutide — and links to the full protocol for each.
What The GLP-1 Class Does
GLP-1 agonists mimic glucagon-like peptide-1, a hormone the gut releases after eating. By activating the same receptors, they slow how quickly the stomach empties, blunt appetite and help regulate blood sugar. Newer compounds in this family also act on the GIP and glucagon receptors, which is why the drugs differ from one another even though they share a common mechanism.
Because they work through the same pathway, these compounds are dosed weekly and are usually titrated — started low and increased in steps — to manage side effects. The three pages below give the vial size, reconstitution, low, medium and high dose, frequency and cycle length for each one.
Compounds In This Class
Tirzepatide
- Vial size
- 60 mg vial
- Dose range
- 2.5–15 mg
Semaglutide
- Vial size
- 12 mg vial
- Dose range
- 0.25–2.4 mg
Retatrutide
- Vial size
- 30 mg vial
- Dose range
- 0.25–12 mg
Dose ranges shown are examples drawn from the research literature for adults and are not medical advice. These are research compounds; most GLP-1 agonists sold for research are not FDA approved for that use.